Avak Kahvejian is the founder of Ampersand Biomedicines. Ampersand Biomedicines has raised $165M in total funding. Latest round: Series B.
Avak Kahvejian is a co-founder of Ampersand Biomedicines, a Boston-based biotechnology company developing programmable biologic medicines designed to target specific organs and tissues. The company utilizes a proprietary computational and experimental platform to engineer targeted therapeutics. Ampersand Biomedicines was founded in 2021 by a team of scientists, and has raised $165 million across three funding rounds, with Flagship Pioneering and Eli Lilly among its investors. Kahvejian, a Flagship General Partner, led early efforts in developing the company's computational tools and multi-omics data platform.
Full founder directory · Investor directory · Company funding database · Fundraising library